

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2012	AC4116135	III	COPD	Adult	NCT: PENDING	A multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of umeclidinium bromide inhalation powder (62.5mcg OR 125mcg) once-daily when added to fluticasone propionate/salmeterol (250/50mcg) twicedaily versus fluticasone propionate/salmeterol (250/50mcg) twice-daily plus placebo over 12 weeks in subjects with COPD
2012	115918 (HBV-323)	IV	Hepatitis B Vaccine	Adult	NCT: PENDING	A Phase IV, Open-label, multi-center study to assess the immunogenicity and safety of GSK Biologicals' hepatitis B vaccine, Engerix-B administered at 0,1 and 6 months in adults with or without type II diabetes mellitus
2012	LIN-MD-04	IIIb	Chronic Constipation with prominent abdominal bloating	Adult	NCT: PENDING	A phase 3b, randomized, double-blind, placebo-controlled, parallel-group trial of linaclotide administered orally for 12 weeks to patients with chronic constipation and prominent abdominal bloating at baseline
2012	RD.03. SPR.29099	III	Severe acne	Adolescent & Adult	NCT01474590	Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Associated With 200 mg Doxycycline Capsules Versus Vehicle Gel Associated With Isotretinoin Capsules in the Treatment of Severe Acne [POWER]
2012	RDEA594-302	III	Gout	Adult	NCT01493531	A Phase 3, Randomized, double-blind, multicenter, placebo-controlled, combination study to evaluate the efficacy and safety of Lesinuard and Allopurinol compared to Allopurinol alone in subjects with Gout who have had an inadequate hypouricemic response to standard of care Allopurinol

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2012	BI-1218.83	IV	Type II Diabetes	Adult	NCT01512979	A 24-week, randomized, double-blind, active-controlled, parallel group trial to assess the superiority of oral linagliptin and metformin compared to linagliptin monotherapy in newly diagnosed, treatment naïve, uncontrolled Type 2 Diabetes Mellitus patients
2011	20090647	IIIb	Plaque Psoriasis	Adult	NCT01313221	A Randomized, Blinded Assessor Study to Evaluate the Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent Versus Etanercept 50 mg Twice Weekly in Subjects with Moderate to Severe Plaque Psoriasis [REFINE]
2011	P05751	III	Ragweed Allergy	Adult	NCT01469182	A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3941) Treatment in Ragweed Allergic Adults
2011	V72_41	III	Meningitis B Vaccine	Adolescent	NCT01423084	A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis rMenB+OMV NZ Vaccine Formulated with OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
2011	114700 (HPV-070-PRI)	IIIb	HPV Vaccine	Adolescent	NCT01381575	A Phase IIIb open-label, randomised, multi-centre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to alternative 2-dose schedules in 9 - 14 year old healthy females compared to the standard 3-dose schedule for GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine in 15 - 25 year old healthy females

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2011	114464 (FLU Q-PAN H5N1- AS03-021)	II/III	H5N1 Vaccine	Adolescent	NCT01310413	A Phase 2/3, randomized, controlled, observer-blind, multi-center trial to evaluate the safety and immunogenicity of a two-dose primary vaccination series of monovalent A/Indonesia/5/2005 (H5N1) vaccine antigen adjuvanted with AS03 in children aged 6 months to < 18 years of age
2011	DB2113374	III	COPD	Adult	NCT01316913	A Multicenter Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
2011	BI-1268.17	III	Asthma	Adult	NCT01092143	A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
2011	Lantu_L_ 04695	IIIb	Type II Diabetes	Adult	NCT01013571	A Canadian, Phase IV, Multicenter, Comparative, Open-label Study Evaluating 2 Approaches of Blood Glucose Monitoring and Insulin Titration (Patient-managed vs Health Care Professional) in T2DM Patients While Receiving the Addition of 1 Injection of Insulin Glulisine at Breakfast Following Optimization of Insulin Glargine
2010	V59_36	IIIb	Meningitis Vaccine	Pediatric	NCT01214837	A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2010	V59_33	III	Meningitis Vaccine	Pediatric	NCT01000311	A Phase 3, Randomized, Open Label, Controlled Multi Center Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
2010	113314 (FLU Q-QIV-003	III	Influenza Vaccine	Pediatric & Adolescent	NCT01198756	A phase III, double blind, randomized study to evaluate the immunogenicity and safety of GSK Biologicals' quadrivalent influenza vaccine candidate, GSK2282512A (FLU Q-QIV), compared to GSK Biologicals' trivalent influenza vaccine Fluarix® administered intramuscularly to children 3 to 17 years of age; and to describe the safety and immunogenicity of GSK2282512A in children 6-35 months of age
2010	28431754-DIA-3008	III	Type II Diabetes	Adult	NCT01032629	A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ 28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
2010	1245.28	III	Type II Diabetes	Adult	NCT01167881	A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Metformin Treatment
2010	NN1250-3724	III	Type II Diabetes	Adult	NCT01068678	A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)
2010	038-002	III	Pain	Adult	NCT: Not Available	A Randomized Crossover Study of a Combination of Controlled-Release Oxycodone and Naloxone (OXN) Controlled-Release Oxycodone HCl Tablets in Patients with Chronic Non-Cancer Pain

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2010	42160443P AI2006	IIb	OA Knee / Pain	Adult	NCT01094262	A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-42160443 as Monotherapy in Subjects With Moderate to Severe, Chronic Knee Pain From Osteoarthritis
2010	113203	II/IIb	Sinusitis	Adolescent & Adults	NCT01018030	A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 2-week Treatment Study to Evaluate the Safety and Efficacy of Fluticasone Furoate Nasal Spray 110 Mcg in the Treatment in the Treatment of Uncomplicated Acute Rhinosinusitis in Adults and Adolescents >= 12 Years of Age
2009	HZC102871	III	COPD	Adult	NCT01009463	A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
2009	D0570C 00003	II	COPD	Adult	NCT00929708	A 4-week, Phase-II, Double-blind, Placebo-controlled, Randomised, Parallel-group, Multi-centre Study to Assess the Efficacy and Tolerability/Safety of Inhaled AZD3199 Once Daily Compared to 9 µg Formoterol Bid and Placebo in Patients With Moderate to Severe COPD (GLAD)
2009	CQAB1 49B2350	IIIb	COPD	Adult	NCT00900731	A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD [INTENSITY]
2009	113482 (FLU Q-PAN H1N1- 003 PRI)	I/II	H1N1 Vaccine	Pediatric	NCT00976820	

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2009	113480 (FLU-Q-PAN H1N1-002 PRI)	III	H1N1 Vaccine	Adult	NCT00979602	A phase II/III, observer-blind, randomized, controlled, multi-center trial to evaluate the safety, immunogenicity, and efficacy of A/California/7/2009 (H1N1)v-like vaccines manufactured in Ste-Foy, Québec in adults aged 18 years and older
2009	DU176b- C-U301	III	Atrial Fibrillation	Adult	NCT00781391	A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of DU-176b Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation [EngageAFTIMI48]
2009	LIN-MD-01	III	Chronic Constipation	Adult	NCT00765882	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks in Patients With Chronic Constipation
2009	LIN-MD-02	III	Chronic Constipation / IBS	Adult	NCT00765999	An Open-Label, Long-Term Safety Study of Oral Linaclotide Administered to Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
2009	LIN-MD-31	III	Chronic Constipation / IBS	Adult	NCT00948818	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks Followed by a 4-Week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
2009	IL1GA-0814	III	Gout	Adult	NCT00855920	A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare
2009	IL1GA-0810	III	Gout	Adult	NCT00829829	A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy [PRE-SURGE1]

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2009	MPX111381	III	Migraine	Adult	NCT00742209	Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache
2009	42160433 PAI2003	IIb	Low Back Pain	Adult	NCT00973024	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately Controlled, Moderate to Severe, Chronic Low Back Pain
2009	42160433 PAI2004	IIb	OA Knee/Hip Pain	Adult	NCT00973141	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Moderate to Severe Knee or Hip Pain From Osteoarthritis
2009	R331333 PAI 3027	III	DPN	Adult	NCT01041859	A Randomized-Withdrawal, Placebo-Controlled, Study Evaluating the Efficacy, Safety, and Tolerability of Tapentadol Extended-Release (ER) in Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
2008	106372 (FLU NG-006 PRI)	III	Influenza Vaccine	Senior	NCT00753272	A Randomized, Observer-blind, Active-Controlled Phase II Study to Demonstrate the Superior Efficacy of GlaxoSmithKline Biologicals' Adjuvanted Influenza Candidate Vaccine, Administered Intramuscularly in Elderly Aged 65 years or above, as compared to Fluarix
2008	110464 (Q-Pan 002)	III	Influenza Vaccine	Adult	NCT00616928	A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccination Regimen in Adults Aged $\geq 18$ Years
2008	111626 (Q-Pan-009)	II	Influenza Vaccine	Adult	NCT00695669	A Trial to Evaluate the Immunogenicity of Investigational Vaccination Regimens With Monovalent A/Indonesia/5/05 (H5N1) Vaccine Antigen in Association With AS03 Adjuvant in Adults Aged 18-64

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2008	111635 (FLU-TF-005)	II	Influenza Vaccine	Pediatric	NCT00778895	A Randomized, Observer-Blind, clinical trial to Assess the Immunogenicity and Safety of Two Dose Levels of Thimerosal-free Fluviral® Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control, administered to children 6 months to less than 3 years of age
2008	V59P20	III	Meningitis Vaccine	Pediatric	NCT00616421	A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
2008	TAK 442_201	II	Musculoskeletal	Adult	NCT00641732	A Phase 2, Randomized, Active Comparator-Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
2008	06CCL3-001	III	Low back pain	Adult	NCT00643383	A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain
2008	R331333 PAI3020	III	OA / Constipation	Adult	NCT00784277	A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Arm, Multicenter Study in Subjects With End-Stage Joint Disease to Compare the Frequency of Constipation Symptoms in Subjects Treated With Tapentadol IR and Oxycodone IR Using a Bowel Function Patient Diary
2008	3200A3-2202	II	Opioid induced bowel dysfunction	Adult	NCT00605644	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Nonmalignant Pain

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2008	MIREC	N/A	Academic/ Observational Study	Adult	N/A	Maternal-Infant Research on Environmental Chemicals (MIREC): A National Profile of In Utero and Lactational Exposure to Environmental Contaminants (Academic/ Observational Study)
2007	CRx-102-006	II	OA	Adult	NCT00521989	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of CRx-102 in Subjects With Symptomatic Knee Osteoarthritis and Optional One-Year Extension
2007	R331333 PAI3010	III	Pain, OA	Adult	NCT00487435	Open-Label Extension, Single-Arm, Flexible-Dosing, Phase 3 Trial With CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain
2007	CRx-401-001	II	Type II Diabetes	Adult	NCT00506298	A Randomized, Multi-Center Study to Compare the Effects of CRx-401 to Bezafibrate Plus Placebo on Plasma Glucose Levels When Given to Subjects With Type II Diabetes on Metformin
2007	3200K1-3356	III	Pain with Constipation	Adult	NCT00529087	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Malignant Pain
2007	110886 HPV-029	III	HPV Vaccine	Adolescent	NCT00578227	Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) Co-administered With a Commercially Available Vaccine in Healthy Female Adolescents
2007	V232-060-01	III	Hepatitis B Vaccine	Adult	NCT00440297	A Study in Renal Predialysis and Dialysis Patients of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process
2007	V121-019	III	Haemophilus Influenzae Type B / Hepatitis B Vaccine	Pediatric	NCT00441012	A Study in Healthy Infant of the Safety, Tolerability, and Immunogenicity of Haemophilus Influenzae, Type b/Hepatitis B Vaccine Manufactured with a Modified Process

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2007	Record 2 BAY 59-7939 (11357)	III	VTE	Adult	NCT00332020	REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-Blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Hip Replacement. [RECORD 2]
2007	Record 4 BAY 59-7939 (11355)	III	VTE	Adult	NCT00362232	REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled, Double-Blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement [RECORD 4]
2006	VGf3554g	II	Diabetic Foot Ulcer	Adult	NCT00351767	A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Diabetic Foot Ulcers
2006	MRSM001	IV	Type II Diabetes	Adult	NCT: Not available	A Feasibility Research Study to Assess Diabetic Control and Treatment Regimens in Patients with Type 2 Diabetes Mellitus
2006	R331333- PAI-3002	III	Pain Management	Adult	NCT00361582	A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease
2006	R331333 PAI-3007	III	Pain, OA	Adult	NCT00361504	A One-Year, Randomized, Open-Label, Parallel-Arm, Phase 3 Long-Term Safety Trial, With Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects With Chronic Pain
2006	CA-101	III	Asthma	Pediatric & Adolescent	NCT00163293	Effect of Low Dose Continuous Treatment With Ciclesonide Over One Year on the Time to First Exacerbation in Children With Mild Asthma Versus Intermittent Treatment for Exacerbations [POPCICLE]

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2006	SKY2028-3-001 Site 1	III	Asthma	Adolescent & Adult	NCT00393991	A Randomized, Double-blind, Placebo-controlled, Parallel, Stratified, Multi-center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm)100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI)With the Administration of Placebo or Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent and Adult Patients With Mild to Moderate Asthma
2006	SKY2028-3-001 Site 2	III	Asthma	Adolescent & Adult	NCT00393991	A Randomized, Double-blind, Placebo-controlled, Parallel, Stratified, Multi-center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm)100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI)With the Administration of Placebo or Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent and Adult Patients With Mild to Moderate Asthma
2006	ADA103575	IV	Asthma & Seasonal Allergic Rhinitis	Adolescent	NCT00385463	A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray Versus Montelukast in Adolescents/Adults With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus(R) or Placebo
2006	COR103561	III	Hypertension	Adult	NCT00273052	A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) With Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2006	D9612L 00096	IV	Gastroesophageal Reflux	Adult	NCT00392002	A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncompASS]
2006	A6061030 Site 1	IIb	Pain after Shingles	Adult	NCT00354094	A Phase 2B Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Postherpetic Neuralgia (PHN)
2006	A6061030 Site 2	IIb	Pain after Shingles	Adult	NCT00354094	A Phase 2B Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Postherpetic Neuralgia (PHN)
2006	ABD106919	IV	Opioid Induced Bowel Dysfunction	Adult	NCT: Not available	An Observational Study to Characterize the Burden of Illness Associated with Laxative Use in Subjects Using Opioids for the Management of Persistent Pain
2005	SB-767905/ 013	III	Opioid Induced Bowel Dysfunction	Adult	NCT00259922	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
2005	SB- 767905/014	III	Opioid Induced Bowel Dysfunction	Adult	NCT00241722	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate Long-Term Safety and Efficacy of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2005	ADG20001	II	Type II Diabetes	Adult	NCT00196989	A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Study To Evaluate Efficacy, Safety And Tolerability Of Oral GW677954 Capsules (2.5, 5, 10, 15 And 20 Mg Once A Day) As A Monotherapy (Diet and/or exercise treated) Or As An Add-On To Metformin For 16 Weeks Duration In Subjects With Type 2 Diabetes Mellitus
2005	AVS101946	III	Type II Diabetes	Adult	NCT00256867	A 16 Week Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of a New Medication (GSK523338) to Lower LDL-c and HbA1c in Subjects With Type 2 Diabetes Mellitus
2005	CCOX189A 2367	III	OA Hip	Adult	NCT00154219	A 13-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control
2005	FKC-010	IV	Renal Transplant	Adult	NCT00902980	Regional Transplant Programs Study of Immunosuppressive Therapy Related Toxicities in Renal Transplant Recipients Managed at Regional or Satellite Community Nephrology Clinics
2004	Gastro- intestinal	IV	Gastrointestinal	Adult	NCT: Not available	LOGIC: A Longitudinal Study of Gastrointestinal Symptoms in Canada
2003	DC-AHS-0006	III	Proteinuria	Adult	NCT00242346	A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to Severe Proteinuria [SMART]

START	PROTOCOL	PHASE	INDICATION	AGE	NCT#	DETAILED TITLE
2002	FE992026 CS002	IV	Nocturnal Enuresis	Pediatric & Adolescent	NCT00245479	An Open Label, Multi-national Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis [DRIP]
2001	49653/048	III	Type II Diabetes	Adult	NCT00279045	A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus [ADOPT: A Diabetes Outcome Progression Trial]
2001	DREAM30 Nov2002	III	Metabolic	Adult	NCT00095654	The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial